Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Employees - 105, CEO - Talat Imran, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -18.98, Piotroski Score(max is 10): 1, Working Capital: $-9550000, Total Assets: $16898000, Retained Earnings: $-116863000, EBIT: -48752000, Total Liabilities: $26051000, Revenue: $1200000

AryaFin Target Price - $-1.22 - Current Price $ - Analyst Target Price $